X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Cipla with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs TEVA PHARMA (Israel) - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 CIPLA   TEVA PHARMA
EQUITY SHARE DATA
    CIPLA
Mar-17
TEVA PHARMA
Dec-13
CIPLA/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs6222,869-   
Low Rs4582,493-   
Sales per share (Unadj.) Rs181.91,646.7-  
Earnings per share (Unadj.) Rs12.9102.9-  
Cash flow per share (Unadj.) Rs29.3236.0-  
Dividends per share (Unadj.) Rs2.0090.05-  
Dividend yield (eoy) %0.43.4 11.0%  
Book value per share (Unadj.) Rs155.71,829.1-  
Shares outstanding (eoy) m804.51848.00-   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.01.6 182.4%   
Avg P/E ratio x42.026.1 161.0%  
P/CF ratio (eoy) x18.411.4 162.2%  
Price / Book Value ratio x3.51.5 236.7%  
Dividend payout %15.587.5 17.8%   
Avg Mkt Cap Rs m434,5162,273,369 19.1%   
No. of employees `00023.044.9 51.3%   
Total wages/salary Rs m26,3380-   
Avg. sales/employee Rs Th6,349.131,068.7 20.4%   
Avg. wages/employee Rs Th1,143.00-   
Avg. net profit/employee Rs Th449.31,940.8 23.2%   
INCOME DATA
Net Sales Rs m146,3021,396,384 10.5%  
Other income Rs m2,2870-   
Total revenues Rs m148,5891,396,384 10.6%   
Gross profit Rs m24,758382,401 6.5%  
Depreciation Rs m13,229112,871 11.7%   
Interest Rs m1,59427,427 5.8%   
Profit before tax Rs m12,222242,102 5.0%   
Minority Interest Rs m01,100 0.0%   
Prior Period Items Rs m-700-   
Extraordinary Inc (Exp) Rs m0-158,927 0.0%   
Tax Rs m1,798-2,956 -60.8%   
Profit after tax Rs m10,35487,231 11.9%  
Gross profit margin %16.927.4 61.8%  
Effective tax rate %14.7-1.2 -1,204.7%   
Net profit margin %7.16.2 113.3%  
BALANCE SHEET DATA
Current assets Rs m87,370943,113 9.3%   
Current liabilities Rs m33,081822,474 4.0%   
Net working cap to sales %37.18.6 429.5%  
Current ratio x2.61.1 230.3%  
Inventory Days Days8791 95.8%  
Debtors Days Days6296 65.0%  
Net fixed assets Rs m111,567456,090 24.5%   
Share capital Rs m1,6093,437 46.8%   
"Free" reserves Rs m123,6450-   
Net worth Rs m125,2541,551,118 8.1%   
Long term debt Rs m36,454714,002 5.1%   
Total assets Rs m209,5323,191,186 6.6%  
Interest coverage x8.79.8 88.2%   
Debt to equity ratio x0.30.5 63.2%  
Sales to assets ratio x0.70.4 159.6%   
Return on assets %5.73.6 158.7%  
Return on equity %8.35.6 147.0%  
Return on capital %8.54.9 172.4%  
Exports to sales %34.20-   
Imports to sales %8.30-   
Net fx Rs m33,3880-   
CASH FLOW
From Operations Rs m23,824222,511 10.7%  
From Investments Rs m-13,127-78,845 16.6%  
From Financial Activity Rs m-13,239-266,917 5.0%  
Net Cashflow Rs m-2,478-123,251 2.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 68.74 Rs / USD

Compare CIPLA With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  

Compare CIPLA With: SANOFI INDIA  DISHMAN PHARMA  ALKEM LABORATORIES  FULFORD INDIA  PIRAMAL ENTERPRISES  



Today's Market

Sensex Ends Day in Green; IT Stocks Lead Gains(Closing)

After opening the day in green, share markets in India witnessed positive trading activity throughout the day and ended the day in above the dotted line.

Related Views On News

CIPLA Announces Quarterly Results (4QFY18); Net Profit Down 347.8% (Quarterly Result Update)

May 24, 2018 | Updated on May 24, 2018

For the quarter ended March 2018, CIPLA has posted a net profit of Rs 2 bn (down 347.8% YoY). Sales on the other hand came in at Rs 37 bn (up 3.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

How to Avoid a 90% Loss Suffered by This Super Investor(The 5 Minute Wrapup)

Jul 12, 2018

Blindly following super investors is a dangerous game to play. Here's how you can avoid such mistakes.

The Answer to Your Wealth Worries: Small Caps (Especially Now)(Profit Hunter)

Jul 10, 2018

If you're worried about the markets - you are on the wrong track. This is opportunity - put your wealth-building hat on, instead - Richa shows you how...

The Multiple Problems with the Minimum Support Price (MSP) System(Vivek Kaul's Diary)

Jul 11, 2018

The price signals that MSP sends out, creates its own set of problems.

ICICI Pru Mutual Fund Tarakki Karega! - The Unethical Way?(Outside View)

Jul 11, 2018

PersonalFN explains how ICICI Prudential Mutual Fund flouted the norms of related party transactions while subscribing to the IPO of ICICI Securities.

PPF v/s Mutual Funds: Which Is Better?(Outside View)

Jul 10, 2018

PersonalFN highlights the key points of distinction between PPF and mutual funds.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Jul 20, 2018 (Close)

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS